Head-to-head · WeighScore
NewSelf vs Henry Meds
The verdict
NewSelf takes it — 85/100 to 76/100.
NewSelf grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Round-$100 semaglutide, $144 tirzepatide, verified and available in all 50 states.
Both are editorial reviews with no commercial relationship.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | NewSelf | Henry Meds |
|---|---|---|
| WeighScore | 85/100 | 76/100 |
| Grade | B | C |
| Scorecard rank | #8 | #25 |
| Semaglutide | $100/mo | $249/mo |
| Tirzepatide | $144/mo | $349/mo |
| Coverage | All 50 states | Multi-state |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| Relationship | Editorial | Editorial |
Graded #8 · B
Strengths
- $100 sema / $144 tirz
- All 50 states, LegitScript-verified
- Both molecules
Where it loses points
- Injection-only
- Labs/monitoring detail sparse
- Limited brand history
Graded #25 · C
Strengths
- Simple flat-fee model
- Established brand
- Both molecules
Where it loses points
- Higher pricing than newer entrants
- Compounded only
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 25 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.